BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma.

Gobin, Bérengère

BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. [electronic resource] - International journal of cancer Feb 2015 - 784-96 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1097-0215

10.1002/ijc.29040 doi


Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Bone Neoplasms--drug therapy
Cell Line, Tumor
Drug Synergism
Female
Humans
Inhibitory Concentration 50
Male
Mice, Inbred C57BL
Mice, Nude
Osteoblasts--drug effects
Osteoclasts--drug effects
Osteosarcoma--drug therapy
Phosphoinositide-3 Kinase Inhibitors
Thiazoles--administration & dosage
Tumor Burden
Xenograft Model Antitumor Assays